Pseudomonas cepacia infection has become increasingly common among patients with cystic fibrosis in North America. In a large cystic fibrosis centre in the United Kingdom 11 cases have been identified during the last six years, with a maximum prevalence of 7% in 1988. Three patients have died, two of whom deteriorated rapidly shortly after acquisition of the organism despite intensive treatment with appropriate antibiotics. Analysis of possible causes of the increase in P cepacia infection suggested that neither patient to patient transmission nor the use of nebulised antibiotics was associated with an increased risk of infection. from 78 to 160. Patients were seen at one of three clinics according to their age: an adult clinic (n =15), an adolescent and young adult clinic (n=60), and a paediatric clinic (n=85). Inpatient admissions were to three separate wards. No attempts were made to segregate patients on the results of sputum cultures. Although inpatients slept and received treatment in separate cubicles, they were not discouraged from ordinary social interaction at other times. The notes of the 160 patients and those who had died during the study period (nine patients) were analysed retrospectively for the incidence of P cepacia infection, clinical scores, use of nebulised antibiotics, and previous contact with other patients infected with P cepacia.
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Most patients with cystic fibrosis die of respiratory failure secondary to chronic bacterial infection with Pseudomonas aeruginosa, Staphylococcus aureus, or Haemophilus influenzae. Recently new species of pseudomonads, in particular Pseudomonas cepacia, have been recognised as important pathogens.' 2 Although some patients remained stable after acquisition of the organism, many showed progressive deterioration. A subgroup of patients who had previously been mildly affected by their disease deteriorated rapidly and died shortly after acquisition of P cepacia. 2 Various risk factors have been suggested as predisposing to infection with P cepacia including increased severity of disease, increased age, recent use of aminoglycoside antibiotics, recent admission to hospital, or a sibling already colonised with the organism.3 ' It is not clear if cross infection is another important contributory factor.5 6 P cepacia has been identified more frequently in patients attending our clinic during the past six years. Two patients who had previously been mildly affected died two months and two years, respectively, after the initial isolation of the organism from their sputum. We were concerned that the regular use of nebulised antibiotics (aminoglycosides and colomycin), to which P cepacia is resistant in vitro, may have been a factor in the development of infection and that patient to patient transmission may have occurred.
We report our experience of P cepacia in the Leeds regional cystic fibrosis unit during the past six years. (table 2) At the end of 1989 the ages of patients attending the clinic ranged from 0-2-33-0 years (mean . The age of patients at the time of their first sputum isolate of P cepacia ranged from 4-7-21-7 years. Five patients were male and six were female. Seven patients were from the paediatric clinic, three from the adolescent clinic, and one from the adult clinic. Infection has so far persisted from 03-4-7 years.
Patients and methods
Three of the 11 patients (27%) have died. One patient (case 5), who was in poor condition at the time of her first infection, died three years later. P cepacia infection was not thought to have influenced her prognosis. Two patients (case 6 and 8) , who had mild to moderate disease, deteriorated rapidly and died two years and two months, respectively, after the onset of infection. Three surviving patients with P cepacia infections have deteriorated quickly, and five remain clinically stable. In the same period six of 88 patients with chronic P aeruginosa infections (7%) have died.
DEVELOPMENT OF INFECTION
Before the isolation of P cepacia, nine patients were infected with P aetuginosa. Subsequently in 10 patients a mixed infection with both pseudomonads persisted. From only one patient was P cepacia alone isolated. After P cepacia was first isolated from six patients, infection became rapidly established with continued growth of the organism in subsequent sputum samples. In three patients, continuous growth was preceded by an eight to 18 month period of intermittent isolations. In the remaining two patients (cases 2 and 3) P cepacia was isolated for four and 12 months, respectively, but later cultures have grown only P aeruginosa.
MICROBIOLOGY
All P cepacia isolates were resistant to colomycin in vitro, and most of them were also resistant to the aminoglycosides (gentamicin, tobramycin, and amikacin) and to ciprofloxacin. Only occasional resistance was found to the ureidopenicillins (piperacillin and azlocillin) or ceftazidime.
Intravenous antibiotic treatment for infected patients was with a combination of either a ureidopenicillin or ceftazidime and an aminoglycoside. Although the P cepacia was usually resistant to the latter, concurrent infection with a P aeruginosa sensitive to aminoglycosides justified this practice.
PATIENTS' CONTACTS
Four of the 11 patients colonised with P cepacia had no known contacts with other similarly infected patients during the six month period before their own first sputum isolation. Seven patients had few contacts (one to five potential contacts at outpatient clinics), and only one patient had prolonged inpatient contacts with known infected cases. During the two years before the isolation of P cepacia, patients had not been admitted any more frequently for intravenous antibiotic treatment than patients infected with other pseudomonads. They had had between 0-4 courses of treatment. Two of the 11 patients infected with P cepacia are siblings. The organism was not isolated from the sputum of the younger (case 4) until three years after the initial isolation from her elder sister (case 5). A further patient continues to be colonised only with P aeruginosa 19 months after isolation of P cepacia from her younger sibling (case 2), although the organism has not recently been isolated from the latter. Two patients (cases 6 and 8) had visited North America at two and four months, respectively, before they became infected with P cepacia. Both had been on trips to Disneyland sponsored by charity, and had mixed freely with other children with cystic fibrosis. NEBULISED 
ANTIBIOTICS
There were 99 patients (including nine dead) who had chronic pseudomonal infection. Forty of the 88 patients infected with P aeruginosa (45%) were having regular treatment with nebulised antibiotics. Of the 11 patients infected with P cepacia five (45%) had received nebulised antibiotics. This suggests that there was no association between the use of nebulised antibiotics and the development of infection.
The following case report of a fulminating infection illustrates the potential of infection with P cepacia to cause an irrevocable accelerated deterioration in lung function in patients previously only mildly affected. recorded as 1-3 1 and 2-9 1, respectively. Despite intensive treatment including intravenous ceftazidime 6 g daily, aztreonam 2 g three times a day, and lincomycin 600 mg four times a day, parenteral feeds, and supplementary oxygen, there was no improvement.
Six days after admission P cepacia was cultured from inital sputum samples. His weight had fallen to 42-6 kg by 22 days, and FEV, and FVC to 0-77 1 and 1-57 1, 15% and 28% of predicted values, respectively. At this stage a minitracheostomy (Mini-trach, Portex Ltd, Kent) was carried out, hourly suction of sputum was started, nasogastric feeds were increased gradually to supply 2 508 MJ (6000 kcal)/day and the dose of ceftazidime was increased to 16 g daily. Despite initial improvement (the fever settled over the next five days, his weight increased to 46-3 kg over the next two weeks, and P cepacia was eradicated from his sputum) the patient had a respiratory arrest. After ventilation and additional treatment with endotracheal and nebulised ceftazidime, a multiresistant Pseudomonas stutzeri was grown from sputum cultures. He died two months after P cepacia had first been isolated from his sputum, and 2 5 months after his previous discharge when he had been in good clinical condition. Discussion This is the first report to our knowledge of P cepacia infection in a large cystic fibrosis centre in the United Kingdom. The pattern of infection mirrors the experience in North America with patients showing one of three responses to the organism.' 2 They remained clinically stable, they deteriorated gradually over a period of months or years, or-in some previously mildly affected cases-they deteriorated rapidly. Although the prevalence of P cepacia infection that we have reported is lower than that reported from North America, centres in the United Kingdom might expect a greater incidence of new cases as numbers attending clinics increase. 8 As illustrated by our case report, if patients lose their lung function rapidly, intensive treatment and eventual eradication ofP cepacia from the sputum cannot prevent respiratory failure secondary to extensive lung damage. In similar cases histological examination of the lungs has shown widespread necrotising pneumonia with formation of microabcesses.9 These changes were more severe and extensive than those in specimens obtained from patients infected with P aeruginosa. Although potential virulence factors have been identified it is not known why infection in some patients follows this fulminating course.'0
The reasons for the increased prevalence of P cepacia are not clear. A more widespread use of selective growth media may partly explain the increase in cases notified in North America.8 Unless a specific search is made, P cepacia will not be identified as it is often overgrown by other cystic fibrosis pathogens including S aureus and P aeruginosa. Our own laboratories have only used selective media since 1986, but before this were typing all colomycin resistant organisms. It is therefore unlikely that any infected cases were not identified. 
